Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Novartis faces generic drug competition during its transformation pains, expects profits to decline this year

Novartis faces generic drug competition during its transformation pains, expects profits to decline this year

格隆汇格隆汇2026/02/04 06:24
Show original
Glonghui, February 4th|Novartis (NVS.US) expects its profits to decline this year due to further impacts from generic drug competition against its core best-selling heart medication Entresto and others. The company stated on Wednesday that, at constant exchange rates, core operating income may see a low single-digit decrease. Sales are expected to grow by a low single-digit percentage. CEO Vas Narasimhan’s strategy of focusing on innovative medicines will be tested this year, as Entresto and other established best-sellers are under pressure from generic competitors. Currently, Novartis is launching a new drug for autoimmune skin diseases and will soon release key data on experimental therapies for heart disease and multiple sclerosis. Novartis has committed to building seven new facilities in the United States as part of its $23 billion investment plan to expand its manufacturing footprint in the country. A significant portion of this will focus on radioligand therapy (RLT)—a cancer treatment that uses targeted drugs to deliver radioactive isotopes directly to tumors.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

AMD (AMD.US) Enters the "Trillion-Dollar Quantum Track": Partners with PsiQuantum to Develop Fault-Tolerant, Practical-Scale Quantum Infrastructure and Plans to Invest

AMD announced that it has expanded its partnership with PsiQuantum to jointly design infrastructure capable of supporting the operation of fault-tolerant, practical-scale quantum computers.

智通财经•2026/11/13 01:17
AMD (AMD.US) Enters the "Trillion-Dollar Quantum Track": Partners with PsiQuantum to Develop Fault-Tolerant, Practical-Scale Quantum Infrastructure and Plans to Invest

While the industry faces turmoil, "Nvidia-backed" Nscale presses ahead for NYSE listing! New IPO prospectus reveals 1,344% surge in revenue but a quarterly net loss of $1.69 billion

Nscale, a "New Cloud" provider backed by Nvidia, submitted its latest filing for an initial public offering (IPO) in the United States on Thursday.

智通财经•2026/11/13 00:41

AI capital expenditures peak as global stock market profits"shift gears"! Goldman Sachs outlines three major themes for 2027

Goldman Sachs Portfolio Strategy Research Department pointed out that as the artificial intelligence investment boom peaks, global stock market earnings growth is expected to decline by more than half in 2027. However, recent valuation declines have created attractive entry points for long-duration technology growth stocks.

智通财经•2026/11/13 00:37

Nvidia (NVDA.US) CEO resigns, causing U.S. stocks to fall; Dow Jones drops 189 points

The resignation of Nvidia CEO Jensen Huang has triggered management turmoil, coupled with espionage rumors, leading to a broad decline in the New York stock market on the 12th. The Dow Jones Industrial Average closed down 189.40 points, with the S&P 500 and the Nasdaq Composite also posting losses, and small and mid-cap stocks experiencing the largest declines. Although the long-term outlook for AI remains unchanged, individual corporate governance risks are significantly weighing on the sentiment of the technology sector, driving funds to shift toward competitors and non-tech blue-chip stocks.

智通财经•2026/11/13 00:37